Sphingosine kinase 11s associated with gastric cancer progression and poor survival of patients

Clinical Cancer Research

Volumn 15, Issue 4, 2009, Pages 1393-1399

  Li, Wen ^a,b   Yu, Chun Ping ^a   Xia, Jin Tang ^f   Zhang, Ling ^a   Weng, Gui Xiang ^a   Zheng, Hai Qing ^c   Kong, Qing Ii ^a   Hu, Li Juan ^a   Zeng, Mu Sheng ^a   Zeng, Yi Xin ^a   Li, Mengfeng ^d,e   Li, Jun ^d,e   Song, Li Bing ^a,e  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b First Affiliated Hospital   (China)

^c Third Affiliated Hospital   (China)

^d SUN YAT SEN UNIVERSITY   (China)

^e SUN YAT SEN UNIVERSITY   (China)

^f GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; SPHINGOSINE KINASE 1; PHOSPHOTRANSFERASE; SPHINGOSINE KINASE; TUMOR MARKER;

ADULT; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL LINE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; STOMACH CANCER; SURVIVAL TIME; UPREGULATION; WESTERN BLOTTING; AGED; DISEASE COURSE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; STOMACH TUMOR; TUMOR CELL LINE;

ADULT; AGED; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROGNOSIS; RNA, MESSENGER; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 63149167365     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1158     Document Type: Article

References (39)

1. Jemal A.Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. FoukakisT, Lundell L, Gubanski M, et al. Advances in the treatment of patients with gastric adenocarcinoma. Acta Oncol 2007;46:277-85.
3. Harder J, Opitz OG. Gastric cancer-risk factors and medical therapy. Schweiz Rundsch Med Prax 2006; 95:1021 -8.
4. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006;12:354-62.
5. Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist 2005;10 Suppl 3:49-58.
6. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer 2000:88:921 -32.
7. Buell JF, HustedT, Hanaway MJ, et al. Gastric cancer in transplant recipients: detection of malignancy by aggressive endoscopy. Transplant Proc 2002;34: 1784-5.
8. Pyne S, Pyne NJ. Sphingosine 1-phosphate signalling in mammalian cells. Biochem J 2000:349: 385-402.
9. Kluk MJ, HlaT Signaling of sphingosine-l-phosphate via the S1P/EDG-family of G-protein-coupled receptors. Biochim Biophys Acta 2002;1582:72-80.
10. Hla T. Signaling and biological actions of sphingosine 1-phosphate. Pharmacol Res 2003:47:401 -407.
11. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003; 4:397-407.
12. Ozaki H, HlaT, Lee MJ. Sphingosine-l-phosphate signaling in endothelial activation. J Atheroscler Thromb 2003;10:125-31.
13. Buell JF, Husted T, Hanaway MJ, et al. Gastric cancer in transplant recipients: detection of malignancy by aggressive endoscopy. Transplant Proc 2002;34: 1784-5.
14. Le Stunff H, Milstien S, Spiegel S, et al. Generation and metabolism of bioactive sphingosine-l-phosphate. J Cell Biochem 2004;92:882-99.
15. Kariya Y, Kihara A, Ikeda M, et al. Products by the sphingosine kinase/sphingosine 1-phosphate (S1P) lyase pathway but not S1P stimulate mitogenesis. Genes Cells 2005;10:605-15.
16. Liu H, Chakravarty D, Maceyka M, et al. Sphingosine kinases: a novel family of lipid kinases. Prog Nucleic Acid Res Mol Biol 2002;71:493-511.
17. Olivera A, Spiegel S. Sphingosine kinase: a mediator of vital cellular functions. Prostaglandins Other Lipid Mediat 2001;64:123-34.
18. Liu H, Sugiura M, Nava VE, et al. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem 2000; 275:19513-20.
19. Van Brocklyn JR, Jackson CA, Pearl DK, et al. Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol 2005:64: 695-705.
20. Kohno M, Momoi M, Oo ML, et al. Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Mol Cell Biol 2006:26:7211 -23.
21. Le Scolan E, Pchejetski D, Banno Y, et al. Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. Blood 2005;106: 1808-16.
22. Akao Y Banno Y Nakagawa Y et al. High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation. Biochem Bio- phys Res Commun 2006;342:284-90.
23. Kawamori T, Osta W, Johnson KR,et al. Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J 2006;20:386-8.
24. Xia P, Gamble JR, Wang L, et al. An oncogenic role of sphingosine kinase. Curr Biol 2000;10:1527-30.
25. Nava VE, Hobson JP, Murthy S, et al. Sphingosine kinase type 1 promotes estrogen-dependent tumori- genesis of breast cancer MCF-7 cells. Exp Cell Res 2002;281:115-27.
26. Edsall LC, Cuvillier O, Twitty S, et al. Sphingosine kinase expression regulates apoptosis and caspase activation in PC12 cells. J Neurochem 2001:76: 1573-84.
27. Pchejetski D, Golzio M, Bonhoure E, et al. Sphingosine kinase-1 as a chemotherapy sensor in prostate ad-nocarcinoma cell and mouse models. Cancer Res 2005;65:11667-75.
28. French KJ, Upson J J, Keller SIM, et al. Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther 2006;318:596-603.
29. Wu W, Mosteller RD, Broek D. Sphingosine kinase protects lipopolysaccharide-activated macrophages from apoptosis. Mol Cell Biol 2004;24: 7359-69.
30. Wu W, Shu X, Hovsepyan H, et al. VEGF receptor expression and signaling in human bladder tumors. Oncogene 2003:22:3361 -70.
31. Smoot DT, Sewchand J, Young K, et al. A method for establishing primary cultures of human gastric epithelial cells. Methods Cell Sci 2000:22: 133-6.
32. American Joint Committee on Cancer. Manual for staging of cancer. 5th ed. Philadelphia: Lippincott-Ra- ven;1997. p. 65-6.
33. Song LB, Liao WT, Mai HQ, et al. The clinical significance of twist expression in nasopharyngeal carcinoma. Cancer Lett 2006;242:258-65.
34. Geisler SA, Olshan AF, Weissler MC, et al. p16 and p53 protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin Cancer Res 2002;8:3445-53.
35. Fukuoka J, Fujii T, Shih JH, et al. Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res 2004;10:4314-24.
36. Pitson SM, Moretti PAB, Zebol JR, et al. Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J 2003:22:5491 -500.
37. Johnson KR, Becker KP, Facchinetti MM,et al. PKC- dependent activation of sphingosine kinase 1 and translocation to the plasma membrane. J Biol Chem 2002;277:35257-62.
38. Halt NC, Fujita K, Lester RL, Dickson RC. Lcb4p sphingoid base kinase localizes to the Golgi and late endosomes. FEBS Lett 2002;532:97-102.
39. Ruckhaberle E, Rody A, Engels K, et al. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer ResTreat 2007 [Epub ahead of print].